Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8(+) exhausted-like T cells

Atezolizumab (anti-PD-L1) combined with bevacizumab (anti-VEGFA) is the first-line immunotherapy for advanced hepatocellular carcinoma (HCC), but the number of patients who benefit from this regimen remains limited. Here, we combine dual PD-L1 and VEGFA blockade (DPVB) with low-dose radiotherapy (LD...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Siqi, Li, Kun, Wang, Kang, Yu, Haoyuan, Wang, Xiangyang, Shi, Mengchen, Liang, Zhixing, Yang, Zhou, Hu, Yongwei, Li, Yang, Liu, Wei, Li, Hua, Cheng, Shuqun, Ye, Linsen, Yang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673920/
https://www.ncbi.nlm.nih.gov/pubmed/38001101
http://dx.doi.org/10.1038/s41467-023-43462-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673920/
https://www.ncbi.nlm.nih.gov/pubmed/38001101
http://dx.doi.org/10.1038/s41467-023-43462-1

Ejemplares similares